ASTRAZENECA PLC
No SEC Form 4 filings for $AZN in the last 30 days.
See all $AZN insider activity →AstraZeneca has registered a new hypertension drug, Baxfendy, in Russia. The drug is approved as an adjunctive therapy for patients not achieving sufficient blood pressure reduction with three or more medications, according to the company's medical director in Russia and Eurasia.
AstraZeneca announced the FDA granted priority review for Imfinzi (durvalumab) combined with enfortumab vedotin to treat muscle-invasive bladder cancer in patients ineligible for cisplatin chemotherapy. The company expects a decision by Q4 2026. AstraZeneca shares rose 1.4% to 12,568 pence in London. According to the company, approval could set a new standard of care.
AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi plus EV received priority review status in the US for muscle-invasive bladder cancer (MIBC). According to the company, this designation is granted to medicines that offer significant improvements in safety or efficacy. The decision is based on positive results from a Phase III trial.
Over the past 7 days, AlphAI's AI scored 38 news stories mentioning AZN (ASTRAZENECA PLC). Coverage has skewed bullish: 27 bullish, 8 neutral, and 3 bearish.
Recent AZN coverage spans regulation, financial news and technology.
Regulatory approval expands AZN's product portfolio in a new market.
Priority review may accelerate approval, boosting Imfinzi sales and AZN stock.
Potential uplift in AstraZeneca stock as the priority review may accelerate market entry.
The negative trial outcome is likely to pressure AstraZeneca's stock as it curtails first‑line market expansion for the drug.
Extension may support AZN's Australian revenue and mitigate negative sentiment from delisting.
AlphAI scores every news story that mentions AZN with an AI model for sentiment and relevance, and aggregates insider trades from ASTRAZENECA PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
AstraZeneca has registered a new hypertension drug, Baxfendy, in Russia. The drug is approved as an adjunctive therapy for patients not achieving sufficient blood pressure reduction with three or more medications, according to the company's medical director in Russia and Eurasia.
2 min readAstraZeneca announced the FDA granted priority review for Imfinzi (durvalumab) combined with enfortumab vedotin to treat muscle-invasive bladder cancer in patients ineligible for cisplatin chemotherapy. The company expects a decision by Q4 2026. AstraZeneca shares rose 1.4% to 12,568 pence in London. According to the company, approval could set a new standard of care.
2 min readAstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi plus EV received priority review status in the US for muscle-invasive bladder cancer (MIBC). According to the company, this designation is granted to medicines that offer significant improvements in safety or efficacy. The decision is based on positive results from a Phase III trial.
1 min readAstraZeneca (AZN) reported that its Phase III SERENA-4 trial for camizestrant in breast cancer failed to meet the primary endpoint, limiting its market potential. The company's broader oncology portfolio and precision-medicine strategy remain intact, with other trials and established drugs supporting growth.
2 min readAstraZeneca extended PBS access to Zoladex until May 2027, delaying its delisting by six months. The 3.6 mg goserelin implant was initially set to be removed on November 2026. AstraZeneca cited manufacturing costs and inflation for the initial decision. PBS prescriptions can be filled until May 2028. The company is considering a further application for long-term reimbursement.
1 min readAstraZeneca (AZN) launched a study to monitor the long-term safety of eplontersen in transthyretin amyloidosis patients with liver issues. The observational study aims to address safety gaps and guide real-world use. The study was submitted in May 2026 and updated in September 2026, with future milestones tied to data collection. Investors watch for safety signals that could impact AZN's valuation and competitive position.
1 min readAstraZeneca (AZN) is conducting a post-marketing safety study for its Breztri inhaler in Korea. The observational study aims to monitor the drug's real-world performance in chronic lung disease patients. The trial, still recruiting, is part of AZN's effort to confirm and defend Breztri's market position in Asia. Investors watch for safety data that could impact AZN's long-term revenue.
2 min readAstraZeneca received EU approval for Trixeo Aerosphere, a triple-combination asthma inhaler for patients aged 12+ with uncontrolled asthma. The therapy, backed by Phase III trial data, is already marketed as Breztri in other regions. This approval strengthens AstraZeneca's respiratory portfolio and growth strategy.
2 min readNine European pharmaceutical giants, including Sanofi and AstraZeneca, urge Europe to boost competitiveness. They cite $600B in U.S. and China investments, warning of losing ground to global rivals. The companies highlight the sector's historical success and call for government action.
2 min readBagrat Lalayan has joined AstraZeneca as Franchise Head, US Medical Affairs, Breast Cancer. He expressed excitement about working with the company's oncology team and thanked his former employer, Legend Biotech, for the experiences gained.
1 min read
